SerpinA3N deficiency attenuates steatosis and enhances insulin signaling in male mice

Aberrant hepatic lipid metabolism is the major cause of non-alcoholic fatty liver disease (NAFLD) and is associated with insulin resistance and type 2 diabetes. Serine (or cysteine) peptidase inhibitor, clade A, member 3N (SerpinA3N) is highly expressed in the liver; however, its functional role in regulating NAFLD and associated metabolic disorders are not known. Male wildtype and hepatocyte Serpina3N knockout (HKO) mice were fed a control diet, methionine- and choline-deficient diet or high-fat high-sucrose diet to induce NAFLD and markers of lipid metabolism and glucose homeostasis were assessed. SerpinA3N protein was markedly induced in mice with fatty livers. Hepatic deletion of SerpinA3N attenuated steatosis which correlated with altered lipid metabolism genes, increased fatty acid oxidation activity and enhanced insulin signaling in mice with NAFLD. Additionally, SerpinA3N HKO mice had reduced epididymal white adipose tissue mass, leptin, and insulin levels, improved glucose tolerance, and enhanced insulin sensitivity which was associated with elevated insulin-like growth factor binding protein-1 (IGFBP1) and activation of the leptin receptor (LEPR)-STAT3 signaling pathway. Our findings provide a novel insight into the functional role of SerpinA3N in regulating NAFLD and glucose homeostasis.

[Vaginal tubal sterilization: About a series of 158 patients from 2005 to 2021]

OBJECTIVES

The latest recommendations of 2006 on tubal sterilization reported an infectious risk of 1.5 to 2.5% for the vaginal approach. There is, however, limited literature on this approach. The primary objective of our study was to investigate the feasibility of tubal sterilization via posterior colpotomy. The secondary objectives were to study the reproducibility of this approach, the postoperative infection rate after tubal sterilization via posterior colpotomy, to evaluate its peroperative and postoperative morbidity.

METHODS

This retrospective study, conducted at the Antibes's Hospital, included patients over 18 years of age who underwent tubal ligation with clips or bilateral vaginal salpingectomy from 2005 to 2021.

RESULTS

We included a total of 158 patients: 88% by clips and 12% by bilateral salpingectomy. The average operative duration was of 27 minutes. There were no infectious or postoperative complications directly related to the sterilization. There were two failures of the technique, requiring conversion to laparoscopy (1.3%) and four subsequent pregnancies (2.5%).

CONCLUSIONS

We were able to show low morbidity and failure rates with this surgical technique. It, therefore, does not appear to be inferior to the laparoscopic approach. Moreover, it is reproducible technique.

Abstract 047: Variation by Provider in Echocardiographic Surveillance of Mitral Regurgitation

Clinical outcomes after surgical treatment of mitral regurgitation (MR) are worse if intervention occurs after deterioration of left ventricular (LV) size and function. Echocardiographic surveillance of patients with MR is therefore indicated to avoid ventricular remodeling that could worsen patient outcomes. However, overly frequent trans-thoracic echocardiograms (TTEs) can impair access for other patients and reduce value in the delivery of care. Given the balance between timeliness of surveillance and possible over-utilization of TTE in valvular disease, we sought to investigate patient and provider factors contributing to variation in TTE utilization. We hypothesized that there was variation attributable to provider practice even after adjustment for patient characteristics.

We obtained records of all TTEs from 2001-2016 ordered at a large echocardiography laboratory. For each TTE, we linked to patient demographic data from hospital administrative records. To control for both clinical and demographic predictors of frequency of echocardiography, we constructed a hierarchical mixed-effects linear regression model with the individual physician as the random effect in the model. The outcome variable was time interval between TTEs. Intra-class correlation coefficient (ICC) was used to assess the proportion of total variation in the outcome variable due to provider practice, and shrinkage estimates were used to measure the contribution of individual providers.

After application of exclusion criteria, 79,194 TTEs corresponding to 55,663 TTE intervals remained. The mean interval between TTEs was 11.9 months for severe MR, 15.4 months for moderate MR, and 17.6 and 17.7 months for mild and trace MR respectively. After multivariate adjustment, male gender (Rate Ratio (RR) 0.96; 95% CI 0.94-0.98) was associated with shorter follow up, and Hispanic race (RR 1.11; 95% CI 1.01-1.21) was associated with longer follow-up intervals. Eight hundred and sixty-seven physicians were included in the analysis. After adjustment for patient factors, 31% of the variation in intervals was associated with provider practice and 19% of providers (161 of 867) were over-utilizers of TTEs and 24% (210 of 867) were under-utilizers.

We conclude that substantial variation exists in follow up intervals for TTE assessment of MR even after risk-adjustment for clinical and demographic variables, likely due to provider factors including specialty and experience. The association of TTE interval with race and gender warrants further investigation. Improving standardization of follow-up intervals may offer opportunity to reduce both overutilization and underutilization of echocardiography.

Abstract 110: Disparities in TTE Surveillance of Mitral Regurgitation

Valvular heart disease continues to be a significant burden to the U.S. population, and is likely to increase over the next several decades. While major technological advances have been made in repairing or replacing degenerating valves, improved outcomes have not affected all segments of society equally. The source of this disparity in outcomes after treatment of valvular disease is unknown. As clinical outcomes after surgical treatment of valvular disease, and especially mitral regurgitation (MR), are worse if intervention occurs after deterioration of left ventricular (LV) size and function, trans-thoracic echocardiographic (TTE) surveillance of patients with MR is indicated to avoid adverse ventricular remodeling. We hypothesized that patients at a lower socioeconomic status were less likely to receive TTE surveillance for MR within the appropriate guideline-indicated interval.

We obtained records of all TTEs from 2001-2016 ordered at a large echocardiography laboratory and linked each TTE to patient demographic data. The primary outcome was receipt of a TTE within guideline recommended intervals for MR surveillance. Intervals between TTEs were coded as appropriate or inappropriate, and logistic regression was used to assess the association of race and income level with appropriateness while controlling for demographic and clinical factors.

In total 31,058 patients with MR in 106,659 TTEs were assessed in the final cohort. Hispanic patients were less likely to receive appropriate TTEs (OR 0.89; p = 0.0440) than predicted by guidelines. Black race trended towards lower odds of receiving TTEs at appropriate intervals, but was not significant (OR 0.95; p = 0.2946). As patients aged, the odds of having a TTE within the appropriate time interval decreased across all races. Income level was not significantly associated with TTE appropriateness.

We conclude that there are disparities in receipt of timely TTE surveillance, especially associated with Hispanic ethnicity. This may contribute to disparities in clinical outcomes after treatment of valvular disease, and provides an opportunity for care improvement.

Abstract 163: Aortic Valve Replacement Confers a Survival Benefit in Patients With Severe Aortic Insufficiency With Depressed Left Ventricular Ejection Fraction

Background: Although guidelines support aortic valve replacement (AVR) in patients with severe aortic regurgitation (AI) and left ventricular ejection fraction (LVEF) < 50%, severe left ventricular dysfunction (LVEF < 35%) is thought to confer very high surgical risk. The survival benefit associated with surgical intervention, however, is unknown. We evaluated long term outcomes of this patient population with and without surgical intervention.

Methods: To capture patients who did and did not undergo AVR, we queried a single institutions echocardiography database to identify all patients with severe AR and LVEF < 35%. Manual chart review was performed to identify key demographic, clinical, and operative details. This retrospective cohort was then merged with institutional patient data. Due to small sample size and population heterogeneity, corrected group prognosis method was applied, which calculates the adjusted survival curve for each individual using fitted Cox proportional hazard model. Average survival adjusted for co-morbidities and age was then calculated using the weighted average of the individual survival curves.

Results: Of 43 echocardiograms representing 41 unique patients, 40 patients met inclusion criteria. Of those, 18 (45.0%) underwent AVR and 22 (55.0%) were managed medically. After multivariate adjustment, end stage renal disease (HR = 17.633, p =0.0335) and peripheral arterial disease (HR = 6.050, p =0.0180) were associated with increased long term mortality. AVR was associated with decreased mortality (HR = 0.143, p =0.0490, see Figure 1). The mean survival for patients undergoing AVR was 6.3 years. The mean follow-up time was 6.58 years.

Conclusions: Even after adjustment for clinical characteristics and patient age, AVR is associated with increased survival for patients with severe systolic dysfunction and severe aortic insufficiency. Although treatment selection bias cannot be completely eliminated with this retrospective cohort design, these results support performing surgery on this high-risk patient group.

[Central giant cell granuloma in children: Presentation of different therapeutic options]

Central giant cell granuloma (CGCG) is a benign tumor that may be subdivided in a non-aggressive form and an aggressive form. In aggressive forms, tumor size and high recurrence risk need large surgical resections. In order to minimize surgical morbidity, especially in children, medical treatments acting on the tumor proliferation are currently being assessed: steroids (triamcinolone), anti-osteoclastic drugs (calcitonine, alendronate, denosumab), anti-angiogenic drugs (interferon α). However to date, there is no evidence for any superiority of medical over surgical treatment. Complete response is rarely obtained and additional surgery is often necessary to remove the tumor in case of tumor progression, to remove a remnant or to remodel bone. Moreover, these drugs have frequent local or systemic side effects such as osteonecrosis and growth deficiencies.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

BACKGROUND

This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC).

PATIENTS AND METHODS

Patients were randomized 1:1:1 to receive cetuximab plus platinum-based chemotherapy alone (control), or combined with cilengitide 2000 mg 1×/week i.v. (CIL-once) or 2×/week i.v. (CIL-twice). A protocol amendment limited enrolment to patients with epidermal growth factor receptor (EGFR) histoscore ≥200 and closed the CIL-twice arm for practical feasibility issues. Primary end point was progression-free survival (PFS; independent read); secondary end points included overall survival (OS), safety, and biomarker analyses. A comparison between the CIL-once and control arms is reported, both for the total cohorts, as well as for patients with EGFR histoscore ≥200.

RESULTS

There were 85 patients in the CIL-once group and 84 in the control group. The PFS (independent read) was 6.2 versus 5.0 months for CIL-once versus control [hazard ratio (HR) 0.72; P = 0.085]; for patients with EGFR histoscore ≥200, PFS was 6.8 versus 5.6 months, respectively (HR 0.57; P = 0.0446). Median OS was 13.6 for CIL-once versus 9.7 months for control (HR 0.81; P = 0.265). In patients with EGFR ≥200, OS was 13.2 versus 11.8 months, respectively (HR 0.95; P = 0.855). No major differences in adverse events between CIL-once and control were reported; nausea (59% versus 56%, respectively) and neutropenia (54% versus 46%, respectively) were the most frequent. There was no increased incidence of thromboembolic events or haemorrhage in cilengitide-treated patients. αvβ3 and αvβ5 expression was neither a predictive nor a prognostic indicator.

CONCLUSIONS

The addition of cilengitide to cetuximab/chemotherapy indicated potential clinical activity, with a trend for PFS difference in the independent-read analysis. However, the observed inconsistencies across end points suggest additional investigations are required to substantiate a potential role of other integrin inhibitors in NSCLC treatment.

CLINICAL TRIAL REGISTRATION ID NUMBER

NCT00842712.

Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection

BACKGROUND

BRAF was identified as an oncogene in skin melanoma in 2002, and since 2011 has been a therapeutic target in the treatment of metastatic melanoma. The role of BRAF mutation in tumour initiation and the disease course remains to be elucidated.

OBJECTIVES

The main objective of our study was to determine whether there is a relationship between BRAF status and overall survival in patients with a melanoma and a positive sentinel lymph node. We also sought an association between BRAF status and the clinicopathological features of the melanoma. Finally, we looked for a potential heterogeneity of BRAF status in primary and metastatic tumours.

METHODS

All patients (n = 72) treated for melanoma and with a positive sentinel lymph node at the University Hospital of Clermont-Ferrand, France, between January 2000 and January 2010 were enrolled in the study. We investigated BRAF status in primary melanoma and lymph node metastatic tissue in our molecular pathology laboratory and collected the clinical and survival data.

RESULTS

Of the 72 patients, 32 had at least one BRAF mutation. There was a statistically significant difference in overall survival between the BRAF-mutated and wild-type populations. The only clinical feature related to BRAF status was metastatic burden. Of the 25 patients in whom we obtained the status in both locations, five had a discordant result.

CONCLUSIONS

BRAF mutation is an indicator of poor prognosis in patients with stage III melanoma with a positive sentinel lymph node. BRAF status could be used in the staging of this population. BRAF has a role not only in cellular immortalization but also in metastatic spread.

Amphipols from A to Z

Amphipols (APols) are short amphipathic polymers that can substitute for detergents to keep integral membrane proteins (MPs) water soluble. In this review, we discuss their structure and solution behavior; the way they associate with MPs; and the structure, dynamics, and solution properties of the resulting complexes. All MPs tested to date form water-soluble complexes with APols, and their biochemical stability is in general greatly improved compared with MPs in detergent solutions. The functionality and ligand-binding properties of APol-trapped MPs are reviewed, and the mechanisms by which APols stabilize MPs are discussed. Applications of APols include MP folding and cell-free synthesis, structural studies by NMR, electron microscopy and X-ray diffraction, APol-mediated immobilization of MPs onto solid supports, proteomics, delivery of MPs to preexisting membranes, and vaccine formulation.